{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T23:13:09Z","timestamp":1782083589774,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12325-020-01570-0","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T15:02:31Z","timestamp":1606489351000},"page":"758-771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis"],"prefix":"10.1007","volume":"38","author":[{"given":"Jacqueline","family":"Nicholas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmay","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"1570_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","author":"GBD 2016 Multiple Sclerosis Collaborators","year":"2019","unstructured":"GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:269\u201385.","journal-title":"Lancet Neurol"},{"key":"1570_CR2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","volume":"86","author":"P Dilokthornsakul","year":"2016","unstructured":"Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurol. 2016;86:1014\u201321.","journal-title":"Neurol"},{"key":"1570_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00415-008-0743-8","volume":"255","author":"C Hirst","year":"2008","unstructured":"Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008;255:280\u20137.","journal-title":"J Neurol"},{"key":"1570_CR4","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","volume":"61","author":"FD Lublin","year":"2003","unstructured":"Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurol. 2003;61:1528\u201332.","journal-title":"Neurol"},{"key":"1570_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","volume":"343","author":"C Confavreux","year":"2000","unstructured":"Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430\u20138.","journal-title":"N Engl J Med"},{"key":"1570_CR6","first-page":"e11","volume":"19","author":"K Karampampa","year":"2012","unstructured":"Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol. 2012;19:e11-25.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"1570_CR7","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awq076","volume":"133","author":"E Leray","year":"2010","unstructured":"Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133:1900\u201313.","journal-title":"Brain"},{"key":"1570_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","volume":"85","author":"A Scalfari","year":"2014","unstructured":"Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:67\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1570_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awh721","volume":"129","author":"M Kremenchutzky","year":"2006","unstructured":"Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129:584\u201394.","journal-title":"Brain"},{"key":"1570_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12913-020-05664-x","volume":"20","author":"M Moccia","year":"2020","unstructured":"Moccia M, Loperto I, Lanzillo R, et al. Persistence, adherence, healthcare resource utilisation and costs for interferon beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). BMC Health Serv Res. 2020;20:797.","journal-title":"BMC Health Serv Res"},{"key":"1570_CR11","doi-asserted-by":"publisher","first-page":"e0169489","DOI":"10.1371\/journal.pone.0169489","volume":"12","author":"M Moccia","year":"2017","unstructured":"Moccia M, Palladino R, Lanzillo R, et al. Healthcare costs for treating relapsing multiple sclerosis and the risk of progression: a retrospective Italian cohort study from 2001 to 2015. PLoS One. 2017;12:e0169489.","journal-title":"PLoS One"},{"key":"1570_CR12","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.18553\/jmcp.2013.19.s1.S41","volume":"19","author":"GM Owens","year":"2013","unstructured":"Owens GM, Olvey EL, Skrepnek GH, Pill MW. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013;19:S41-53.","journal-title":"J Manag Care Pharm"},{"key":"1570_CR13","first-page":"S151","volume":"22","author":"GM Owens","year":"2016","unstructured":"Owens GM. Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management. Am J Manag Care. 2016;22:S151\u20138.","journal-title":"Am J Manag Care"},{"key":"1570_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1472-6963-3-17","volume":"3","author":"JA O'Brien","year":"2003","unstructured":"O\u2019Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3:17.","journal-title":"BMC Health Serv Res"},{"key":"1570_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.msard.2014.09.002","volume":"3","author":"K O'Connell","year":"2014","unstructured":"O\u2019Connell K, Kelly SB, Fogarty E, et al. Economic costs associated with an MS relapse. Mult Scler Relat Disord. 2014;3:678\u201383.","journal-title":"Mult Scler Relat Disord"},{"key":"1570_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2013.04.007","volume":"330","author":"H Parise","year":"2013","unstructured":"Parise H, Laliberte F, Lefebvre P, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci. 2013;330:71\u20137.","journal-title":"J Neurol Sci"},{"key":"1570_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12913-016-1532-1","volume":"16","author":"E Jones","year":"2016","unstructured":"Jones E, Pike J, Marshall T, Ye X. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US. BMC Health Serv Res. 2016;16:294.","journal-title":"BMC Health Serv Res"},{"key":"1570_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2010.523670","volume":"13","author":"BJ Chastek","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13:618\u201325.","journal-title":"J Med Econ"},{"key":"1570_CR19","unstructured":"Genzyme. AUBAGIO (teriflunomide) tablets, for oral use. Prescribing information. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202992s002lbl.pdf. Accessed Nov 2016."},{"key":"1570_CR20","unstructured":"Biogen. AVOneX (interferon beta-1a) injection, for intramuscular injection. Prescribing information. 2016. https:\/\/www.avonex.com\/content\/dam\/commercial\/multiple-sclerosis\/avonex\/pat\/en_us\/pdf\/Avonex_Prescribing_Information.pdf. Accessed Mar 2016."},{"key":"1570_CR21","unstructured":"EMD Serono. REBIF (interferon beta-1a), for subcutaneous injection. Prescription information. 2015. https:\/\/www.emdserono.com\/content\/dam\/web\/corporate\/non-images\/country-specifics\/us\/pi\/rebif-pi.pdf. Accessed Nov 2015."},{"key":"1570_CR22","unstructured":"Bayer Health Care. BETASERON (interferon beta-1b) for injection, for subcutaneous use. Prescribing information. 2016. http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Betaseron_PI.pdf. Accessed Mar 2017."},{"key":"1570_CR23","unstructured":"Novartis. EXTAVIA (interferon beta-1b) for injection, for subcutaneous use. Prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125290s066lbl.pdf. Accessed Dec 2018."},{"key":"1570_CR24","unstructured":"Novartis. GILENYA (fingolimod) capsules, for oral use. Prescribing information. 2016. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/gilenya.pdf. Accessed Mar 2017."},{"key":"1570_CR25","unstructured":"Biogen. TYSABRI (natalizumab) injection, for intravenous use. Prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125104s960s963lbl.pdf. Accessed Apr 2018."},{"key":"1570_CR26","unstructured":"Teva Neuroscience. Copaxone (glatiramer acetate injection) for subcutaneous use. Prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020622s104lbl.pdf. Accessed Sep 2018."},{"key":"1570_CR27","unstructured":"Genzyme. LEMTRADA (alemtuzumab) injection, for intravenous use. Prescribing information. 2016. http:\/\/products.sanofi.us\/lemtrada\/lemtrada.pdf. Accessed Aug 2017."},{"key":"1570_CR28","doi-asserted-by":"publisher","first-page":"e0222012","DOI":"10.1371\/journal.pone.0222012","volume":"14","author":"M Moccia","year":"2019","unstructured":"Moccia M, Tajani A, Acampora R, et al. Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: comparison between centre-based and local service healthcare delivery. PLoS One. 2019;14:e0222012.","journal-title":"PLoS One"},{"key":"1570_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3111\/13696998.2012.667027","volume":"15","author":"JI Ivanova","year":"2012","unstructured":"Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15:601\u20139.","journal-title":"J Med Econ"},{"key":"1570_CR30","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3111\/13696998.2013.823868","volume":"16","author":"MJ Lage","year":"2013","unstructured":"Lage MJ, Carroll CA, Fairman KA. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment. J Med Econ. 2013;16:1146\u201353.","journal-title":"J Med Econ"},{"key":"1570_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/11592160-000000000-00000","volume":"5","author":"M Oleen-Burkey","year":"2012","unstructured":"Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse: the patient\u2019s perspective. Patient. 2012;5:57\u201369.","journal-title":"Patient"},{"key":"1570_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1352458517708125","volume":"23","author":"C Lebrun-Frenay","year":"2017","unstructured":"Lebrun-Frenay C, Kobelt G, Berg J, Capsa D, Gannedahl M, Sclerosis EM. New insights into the burden and costs of multiple sclerosis in Europe: results for France. Mult Scler J. 2017;23:65\u201377.","journal-title":"Mult Scler J"},{"key":"1570_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1352458517708141","volume":"23","author":"P Flachenecker","year":"2017","unstructured":"Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M, Sclerosis EM. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany. Mult Scler J. 2017;23:78\u201390.","journal-title":"Mult Scler J"},{"key":"1570_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1352458517708176","volume":"23","author":"M Battaglia","year":"2017","unstructured":"Battaglia M, Kobelt G, Ponzio M, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Italy. Mult Scler J. 2017;23:104\u201316.","journal-title":"Mult Scler J"},{"key":"1570_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/1352458517708672","volume":"23","author":"C Oreja-Guevara","year":"2017","unstructured":"Oreja-Guevara C, Kobelt G, Berg J, Capsa D, Eriksson J, Sclerosis EM. New insights into the burden and costs of multiple sclerosis in Europe: results for Spain. Mult Scler J. 2017;23:166\u201378.","journal-title":"Mult Scler J"},{"key":"1570_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/1352458517708687","volume":"23","author":"A Thompson","year":"2017","unstructured":"Thompson A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for the United Kingdom. Mult Scler J. 2017;23:204\u201316.","journal-title":"Mult Scler J"},{"key":"1570_CR37","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J. 2017;23:1123\u201336.","journal-title":"Mult Scler J"},{"key":"1570_CR38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3111\/13696998.2013.807267","volume":"16","author":"K Karampampa","year":"2013","unstructured":"Karampampa K, Gustavsson A, van Munster ET, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in the Netherlands. J Med Econ. 2013;16:939\u201350.","journal-title":"J Med Econ"},{"key":"1570_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3111\/13696998.2014.950420","volume":"18","author":"R Karabudak","year":"2015","unstructured":"Karabudak R, Karampampa K, Caliskan Z, Group TS. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey. J Med Econ. 2015;18:69\u201375.","journal-title":"J Med Econ"},{"key":"1570_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1472-6963-13-131","volume":"13","author":"K Raimundo","year":"2013","unstructured":"Raimundo K, Tian H, Zhou H, et al. Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity. BMC Health Serv Res. 2013;13:131.","journal-title":"BMC Health Serv Res"},{"key":"1570_CR41","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s10198-015-0728-3","volume":"17","author":"AJ Hawton","year":"2016","unstructured":"Hawton AJ, Green C. Multiple sclerosis: relapses, resource use, and costs. Eur J Health Econ. 2016;17:875\u201384.","journal-title":"Eur J Health Econ"},{"key":"1570_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cen3.12299","volume":"7","author":"M Ogino","year":"2016","unstructured":"Ogino M, Kawachi I, Otake K, et al. Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database. Clin Exp Neuroimmunol. 2016;7:158\u201367.","journal-title":"Clin Exp Neuroimmunol"},{"key":"1570_CR43","unstructured":"Institute for Clinical and Economic Review. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value. Final evidence report. March 6, 2017. https:\/\/icer-review.org\/wp-content\/uploads\/2016\/08\/CTAF_MS_Final_Report_030617.pdf. Accessed May 2017."},{"key":"1570_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","volume":"16","author":"B Merkel","year":"2017","unstructured":"Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16:658\u201365.","journal-title":"Autoimmun Rev"},{"key":"1570_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","volume":"13","author":"M Trojano","year":"2017","unstructured":"Trojano M, Tintore M, Montalban X, et al. Treatment decisions in multiple sclerosis\u2014insights from real-world observational studies. Nat Rev Neurol. 2017;13:105\u201318.","journal-title":"Nat Rev Neurol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01570-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T21:36:27Z","timestamp":1612301787000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01570-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01570-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}